Date: _	April. :	18 th , 2022	
Your Na	ame:	YaoYang	
Manuso	cript Title	: Performance o	f AIDRScreening for detecting diabetic retinopathy in the Chinese population: a
prospec	ctive, mu	lti-center clinical	trial
Manuso	cript num	ber (if known):	ATM-22-350

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Funding	This study was Financial supported by Shenzhen SiBright Co. Ltd. in China.
		Time frame: past	26 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	

4	Consulting fees	X None	
4	Consulting rees		
-		V. N	
5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or educational events		
6	Payment for expert	X None	
6	testimony	X_None	
	testimony		
7	Support for attending	X None	
,	meetings and/or travel		
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	_XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	_XNone	
	in other board, society,		
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	X None	
	Stock of Stock options		
12	Receipt of equipment,	X None	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	X None	
	financial interests		

The study was funded by Shenzhen SiBright Co.Ltd, and the author has received the written approval from Shenzhen SiBright Co.Ltd regarding this publication.

Please place an "X" next to the following statement to indicate your agreement:

Date:	April. 1	8 th , 2022	
Your Na	me:	Jianying Pan	
Manusci	ript Title:	Performance of AIDRScreening for detec	cting diabetic retinopathy in the Chinese population: a
prospect	tive, mult	ti-center clinical trial	
Manusci	ript numb	per (if known): ATM-22-350	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Funding	This study was Financial supported by Shenzhen SiBright Co. Ltd. in China.
		T:	26 marship
2	Grants or contracts from	Time frame: past	50 Months
	any entity (if not indicated in item #1 above).	_X _None	
3	Royalties or licenses	_X _None	

4	Consulting fees	_X _None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	_X _None	
6	Payment for expert testimony	_X _None	
7	Support for attending meetings and/or travel	_X _None	
8	Patents planned, issued or pending	_X _None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	_X _None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	_X _None	
11	Stock or stock options	_X _None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	_X _None	
13	Other financial or non- financial interests	_X _None	

The study was funded by Shenzhen SiBright Co.Ltd, and the author has received the written approval from Shenzhen SiBright Co.Ltd regarding this publication.

Please place an "X" next to the following statement to indicate your agreement:

Date: _	Αp	oril. 12	^{2th} , 2022
Your N	ame:		Miner Yuan
Manus	cript	Title:	Performance of AIDRScreening for detecting diabetic retinopathy in the Chinese population: a
prospe	ctive	, mult	i-center clinical trial
Manus	crint	numh	er (if known): ATM-22-350

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Funding	This study was Financial supported by Shenzhen SiBright Co. Ltd. in China.
		Time frame, nect	26 months
2	Crants or contracts from	Time frame: past	56 Months
2	Grants or contracts from any entity (if not indicated	XNone	
	in item #1 above).		
3	Royalties or licenses	_XNone	

4	Consulting fees	X None
·	22	
5	Payment or honoraria for	XNone
	lectures, presentations,	
	speakers bureaus, manuscript writing or	
	educational events	
6	Payment for expert	XNone
	testimony	
7	Support for attending meetings and/or travel	XNone
	G ,	
8	Patents planned, issued or	XNone
	pending	
9	Participation on a Data	XNone
	Safety Monitoring Board or Advisory Board	
10	Leadership or fiduciary role	X None
10	in other board, society,	
	committee or advocacy	
	group, paid or unpaid	
11	Stock or stock options	XNone
12	Receipt of equipment,	X_None
	materials, drugs, medical	
	writing, gifts or other	
	services	
13	Other financial or non- financial interests	X_None
	iiiialitiai iiiterests	

The study was funded by Shenzhen SiBright Co.Ltd, and the author has received the written approval from Shenzhen SiBright Co.Ltd regarding this publication.

Please place an "X" next to the following statement to indicate your agreement:

Date: _	Ar	oril. 16	^{3th} , 2022
Your N	lame:		Kunbei Lai
Manus	cript	Title:	Performance of AIDRScreening for detecting diabetic retinopathy in the Chinese population: a
prospe	ective	, multi	i-center clinical trial
Manus	crint	numh	er (if known): ATM-22-350

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Funding	This study was Financial supported by Shenzhen SiBright Co. Ltd. in China.
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	X None	

4	Consulting fees	_X None	
5	Payment or honoraria for	X_None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or educational events		
6	Payment for expert	X None	
U	testimony	ANOTE	
	cestimony		
7	Support for attending	X None	
	meetings and/or travel		
	.		
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society,		
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	X None	
11	Stock of Stock options	NNOTICE	
12	Receipt of equipment,	X None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	XNone	
	financial interests		
Dla-		nflict of interest in the following how	

The study was funded by Shenzhen SiBright Co.Ltd, and the author has received the written approval from Shenzhen SiBright Co.Ltd regarding this publication.

Please place an "X" next to the following statement to indicate your agreement:

Date: _	April. 18 th , 2022
Your Na	ame: Huirui Xie
Manus	cript Title: Performance of AIDRScreening for detecting diabetic retinopathy in the Chinese population: a
prospe	ctive, multi-center clinical trial
Manus	cript number (if known): ATM-22-350

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Funding	This study was Financial supported by Shenzhen SiBright Co. Ltd. in China.
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	_X_None	
3	Royalties or licenses	_X _None	

4	Consulting fees	_X _None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	_X _None	
6	Payment for expert testimony	_X _None	
7	Support for attending meetings and/or travel	_X _None	
8	Patents planned, issued or pending	_X _None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	_X _None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	_X _None	
11	Stock or stock options	_X _None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	_X _None	
13	Other financial or non- financial interests	_X _None	

The study was funded by Shenzhen SiBright Co.Ltd, and the author has received the written approval from Shenzhen SiBright Co.Ltd regarding this publication.

Please place an "X" next to the following statement to indicate your agreement:

Date: April. 18 th , 2022	
Your Name: Li Ma	
Manuscript Title: Performance of AID	RScreening for detecting diabetic retinopathy in the Chinese population: a
prospective, multi-center clinical trial	
Manuscrint number (if known): ATM	1-22-350

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present		
1	All support for the present manuscript (e.g., funding,	Funding	This study was Financial supported by Shenzhen SiBright Co. Ltd. in China.
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	X None	30 Mondis
_	any entity (if not indicated	_X_None	
	in item #1 above).		
3	Royalties or licenses	_X _None	

4	Consulting fees	_X _None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	_X _None	
6	Payment for expert testimony	_X _None	
7	Support for attending meetings and/or travel	_X _None	
8	Patents planned, issued or pending	_X _None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	_X _None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	_X _None	
11	Stock or stock options	_X _None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	_X _None	
13	Other financial or non- financial interests	_X _None	

The study was funded by Shenzhen SiBright Co.Ltd, and the author has received the written approval from Shenzhen SiBright Co.Ltd regarding this publication.

Please place an "X" next to the following statement to indicate your agreement:

Date:	April. 19 th , 2022
Your Name	e: Suzhong Xu
Manuscrip	ot Title: Performance of AIDRScreening for detecting diabetic retinopathy in the Chinese population: a
prospectiv	ve, multi-center clinical trial
Manuscrip	ot number (if known): ATM-22-350

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

			Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
L			Time frame: Since the initial	planning of the work
	1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Funding	This study was Financial supported by Shenzhen SiBright Co. Ltd. in China.
			Time frame: past	36 months
	2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
	3	Royalties or licenses	XNone	

4	Consulting fees	_XNone	
5	Dayment or honoraria for	V None	
Э	Payment or honoraria for lectures, presentations,	XNone	
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	XNone	
	testimony		
-	6 16 11 12	V N	
7	Support for attending meetings and/or travel	XNone	
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	_XNone	
	Safety Monitoring Board or Advisory Board		
10		V. Name	
10	Leadership or fiduciary role in other board, society,	_XNone	
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	XNone	
12	Receipt of equipment,	XNone	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	X_None	
	financial interests		

The study was funded by Shenzhen SiBright Co.Ltd, and the author has received the written approval from Shenzhen SiBright Co.Ltd regarding this publication.

Please place an "X" next to the following statement to indicate your agreement:

Date:	April. 19 th , 2022
Your Na	ame: Ruzhi Deng
Manusc	cript Title: Performance of AIDRScreening for detecting diabetic retinopathy in the Chinese population: a
prospec	ctive, multi-center clinical trial
Manusc	cript number (if known): ATM-22-350

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present	Funding	This study was Financial supported by Shenzhen SiBright
-	manuscript (e.g., funding,	Fulluling	Co. Ltd. in China.
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time from a most	26
2	Grants or contracts from	Time frame: past X None	36 Months
-	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	XNone	

4	Consulting fees	_XNone
5	Payment or honoraria for	XNone
	lectures, presentations, speakers bureaus,	
	manuscript writing or	
	educational events	
6	Payment for expert	XNone
	testimony	
-	C 1 C 11 E	V N
7	Support for attending meetings and/or travel	XNone
8	Patents planned, issued or	XNone
	pending	
	5	N A
9	Participation on a Data Safety Monitoring Board or	_XNone
	Advisory Board	
10	Leadership or fiduciary role	X None
	in other board, society,	
	committee or advocacy	
	group, paid or unpaid	
11	Stock or stock options	XNone
12	Receipt of equipment,	X None
12	materials, drugs, medical	<u>X_None</u>
	writing, gifts or other	
	services	
13	Other financial or non-	X_None
	financial interests	

The study was funded by Shenzhen SiBright Co.Ltd, and the author has received the written approval from Shenzhen SiBright Co.Ltd regarding this publication.

Please place an "X" next to the following statement to indicate your agreement:

Date: _	Apı	ril. 19 th	. 2022	
Your N	lame: _	М	ingwei Zhao	
Manus	cript T	itle: P	erformance o	of AIDRScreening for detecting diabetic retinopathy in the Chinese population: a
prospe	ctive,	multi-c	enter clinical	trial
Manus	cript n	number	(if known):	ATM-22-350

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

			Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
L			Time frame: Since the initial	planning of the work
	1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Funding	This study was Financial supported by Shenzhen SiBright Co. Ltd. in China.
			Time frame: past	36 months
	2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
	3	Royalties or licenses	XNone	

4	Consulting fees	_XNone
5	Payment or honoraria for	XNone
	lectures, presentations, speakers bureaus,	
	manuscript writing or	
	educational events	
6	Payment for expert	XNone
	testimony	
7	Support for attending meetings and/or travel	XNone
8	Patents planned, issued or	XNone
	pending	
9	Participation on a Data	_XNone
	Safety Monitoring Board or Advisory Board	
10	Leadership or fiduciary role	X None
10	in other board, society,	XNone
	committee or advocacy	
	group, paid or unpaid	
11	Stock or stock options	XNone
10		W. N.
12	Receipt of equipment, materials, drugs, medical	XNone
	writing, gifts or other	
	services	
13	Other financial or non-	XNone
	financial interests	

The study was funded by Shenzhen SiBright Co.Ltd, and the author has received the written approval from Shenzhen SiBright Co.Ltd regarding this publication.

Please place an "X" next to the following statement to indicate your agreement:

Date: _	Ap	ril. 12	^h , 2022
Your N	ame:	•	an Luo
Manus	cript T	Title:	Performance of AIDRScreening for detecting diabetic retinopathy in the Chinese population: a
prospe	ctive,	multi	center clinical trial
Manus	crint r	numh	r (if known): ATM-22-350

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	
1	All support for the present manuscript (e.g., funding,	Funding	This study was Financial supported by Shenzhen SiBright Co. Ltd. in China.
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	XNone	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	XNone	

4	Consulting fees	XNone
5	Payment or honoraria for	XNone
	lectures, presentations, speakers bureaus,	
	manuscript writing or	
	educational events	
6	Payment for expert testimony	XNone
	,	
7	Support for attending meetings and/or travel	XNone
8	Patents planned, issued or	XNone
	pending	
9	Participation on a Data	X None
	Safety Monitoring Board or	
	Advisory Board	
10	Leadership or fiduciary role in other board, society,	XNone
	committee or advocacy	
	group, paid or unpaid	
11	Stock or stock options	XNone
12	Receipt of equipment,	XNone
	materials, drugs, medical	
	writing, gifts or other services	
13	Other financial or non-	XNone
	financial interests	

The study was funded by Shenzhen SiBright Co.Ltd, and the author has received the written approval from Shenzhen SiBright Co.Ltd regarding this publication.

Please place an "X" next to the following statement to indicate your agreement:

Date:	April. 12	^{2th} , 2022
Your Nar	ne:	Xiaofeng Lin
Manuscr	ipt Title:	Performance of AIDRScreening for detecting diabetic retinopathy in the Chinese population: a
prospect	ive, mult	i-center clinical trial
Manuscr	int numb	er (if known): ATM-22-350

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Funding	This study was Financial supported by Shenzhen SiBright Co. Ltd. in China.
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	

4	Consulting fees	XNone		
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	XNone		
6	Payment for expert testimony	XNone		
7	Support for attending meetings and/or travel	XNone		
8	Patents planned, issued or pending	XNone		
9	Participation on a Data Safety Monitoring Board or Advisory Board	XNone		
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	XNone		
11	Stock or stock options	XNone		
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	XNone		
13	Other financial or non- financial interests	XNone		
Ple	Please summarize the above conflict of interest in the following box:			

The study was funded by Shenzhen SiBright Co.Ltd, and the author has received the written approval from Shenzhen SiBright Co.Ltd regarding this publication.

Please place an "X" next to the following statement to indicate your agreement: